Rubicon Research Ltd

The transcript provided does not explicitly mention the current or expected order book or pending orders of Rubicon Research Limited. However, relevant points related to demand and production are: - Demand has been higher than anticipated, leading to increased outsourcing to meet customer needs. - Sales ramp-up has exceeded expectations. - The company is operationalizing the Pithampur facility by mid-2026, aiming for commercialization in Q1 of CY 2027 to scale up in-house manufacturing. - The focus is on locking in demand and ensuring supply chain reliability to maintain customer faith. - Management is confident about strong growth trajectory and stable operating EBITDA margins amid high demand. - They continue to pursue global market expansions with registrations underway in new geographies. No specific figures or details on the order book or pending orders were provided in the call.

- As of the latest update, Rubicon Research Limited has not indicated any immediate plans for new fundraising through debt or equity. - The company reported having a cash reserve of INR334 crores, providing sufficient "dry powder" for inorganic growth aspirations. - Debt has been reduced recently, with borrowings at INR285 crores as on December 31, down from INR393 crores in March, indicating repayment efforts rather than new borrowing. - There was no mention of upcoming fundraises or capital raising activities in the current disclosure. - The company appears focused on leveraging existing cash and operational cash flows for growth and acquisitions, such as the recent Pithampur manufacturing facility acquisition.

- The company acquired the Pithampur manufacturing facility in June 2025 to build more capacity and capabilities, including high potent oncology, hormones, and steroids, with room for expansion. - Pithampur is on track for operationalization and validation completion by mid-2026 and expected commercialization by Q1 CY 2027. - Additional capex of around INR 70 crores was made alongside the Pithampur acquisition. - The company holds a cash reserve of INR 334 crores, providing "dry powder" for inorganic growth aspirations. - Evaluations and tactical measures regarding own manufacturing versus outsourcing to optimize margins are ongoing. - There was an investment of INR 18 crores in Gen1E Lifescience as part of strategic investment. - Overall, the company plans to maintain R&D spend at around 10%-11% of revenue, equating to over INR 500 crores over fiscals ‘26-‘28, supporting future growth initiatives.

- The company remains confident in a strong growth trajectory with broad-based revenue growth across both new launches and existing products. - Specialty portfolio contribution to gross profit has increased from around 27% to about 31-32%, and is expected to continue growing. - R&D productivity has improved (from 3.3x to 5.7x revenue multiple over R&D spend), supporting sustainable incremental revenue growth. - Demand environment continues to be strong, with no significant dependency on a single product, indicating diversified growth sources. - The ramp-up of the Pithampur manufacturing facility in CY 2026 - early CY 2027 is expected to aid capacity, supporting revenue growth. - Conservative modeling factors in regulatory and supply risks, ensuring stable and sustainable growth outlook. - Management anticipates that the revenue base could potentially multiply 3x over 5-7 years, driven by innovation, pipeline strength, and commercialization capabilities.

- Rubicon Research remains confident in maintaining a strong growth trajectory into FY ‘27 and ‘28, though specific guidance is not provided. - Operating EBITDA margin is expected to stabilize in the 22%-23% range, supported by ramp-up of the Pithampur facility in CY’27. - R&D productivity is projected to continue at upward of 5x, with a strong and exciting product pipeline enhancing future revenue growth. - Specialty product share in gross profit is increasing (from ~27% in FY ‘25 to 31%-32% currently), expected to contribute more incrementally. - Revenue growth is broad-based with no dependency on any single product, supported by new launches and market share gains. - Adjustments in manufacturing mix (in-house vs outsourcing) and Pithampur ramp-up are expected to positively impact margins over time. - EPS growth is supported by consistent revenue gains and healthy EBITDA margins, with Q3 FY ‘26 EPS at ₹4.41, up 91% YoY.